New research from the labs of MCB Professors Ehud Isacoff & John Flannery reports that insertion of a gene for a green-light receptor into the eyes of blind mice led to signs of reversed retinal degeneration. This gene therapy may soon be used to help restore vision in humans blindness due to retinal degeration.
Show your Blue and Gold spirit by participating in this year's Big Give. This is a chance for us all to come together as an entire Cal commuity—alumni, parents, students, faculty, staff, and friends—to support our favorite department. Even the smallest gift can make a big difference!
This year, we're funding two main initiatives:
- Expand tutoring services: As the MCB major continues to grow, we want to expand our tutoring opportunities to students in upper division MCB courses such as MCB 102, 104, and 110.
- Establish a teaching award for outstanding Graduate Student Instructors (GSIs): MCB GSIs are integral to the success of our undergraduates. This award will recognize their invaluable contribution to teaching excellence.
Consider making a donation to the MCB Department to help us create many more great moments in the future!
New research from the lab of MCB Professor Richard Kramer shows that a new therapy "could help prolong useful vision and delay total blindness" in humans with deteriorating vision. The treatment, which has been successful in trials with mice, utilizes drug or gene therapy to reduce interfering noise generated by nerve cells in the eye. Reduction of this noise can improve vision for those suffering from vision loss, including common age-related macular degeneration.
“This isn’t a cure for these diseases, but a treatment that may help people see better. This won’t put back the photoreceptors that have died, but maybe give people an extra few years of useful vision with the ones that are left,” says Kramer.
Congratulations to Associate Professor of MCB, NST & Chemistry Daniel Nomura for winning an ASPIRE Award from the Mark Foundation for Cancer Research! This award "funds high risk, high reward approaches to solving complex problems in cancer research that tend to fall outside the scope of other funding opportunities."
Nomura's lab is mapping hotspots of binding sites in human proteins that have been traditionally considered "undruggable" and developing novel small molecule drugs that bind to those proteins.